Key facts
- This page summarizes Camille L. Bedrosian's Form 4 filing for RHYTHM PHARMACEUTICALS, INC. (RYTM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 23 Jun 2025, 16:52.
Camille L. Bedrosian - 18 Jun 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)
- Reporting relationship
- Director
- Issuer ticker
- RYTM
- Reported as of
- 18 Jun 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Jun 2025, 16:52:05 UTC
- Prior SEC filing
- 13 Jun 2025
- Next SEC filing
- 26 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen Vander Stoep, attorney-in-fact for Camille L. Bedrosian
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Camille L. Bedrosian filed Form 4 for RHYTHM PHARMACEUTICALS, INC. (RYTM) on 23 Jun 2025.
Change
- Previous filing in this sequence was filed on 13 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001326969
Primary reporting owner
Bedrosian Camille L
- Relationship
- Director
- Address
- 222 BERKELEY STREET, 12TH FLOOR, BOSTON
- Signature
- /s/ Stephen Vander Stoep, attorney-in-fact for Camille L. Bedrosian
- Signature date
- 23 Jun 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RYTM
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +4,000
- Change %
- +133%
- Price
- Shares after
- 7,000
- Date
- 18 Jun 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RYTM
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -4,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 18 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,000
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
Footnote F2
The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date.